Examkin

Question

Difficulty: MediumNeoplastic Processes

A 6464-year-old woman is evaluated in the oncology clinic to discuss systemic therapy for newly diagnosed metastatic colorectal cancer. Two weeks ago, she underwent a right hemicolectomy for an obstructing cecal mass. Intraoperative findings and subsequent imaging confirmed the presence of unresectable bilobar hepatic metastases. Pathology of the primary tumor demonstrated moderately differentiated adenocarcinoma. Comprehensive molecular profiling of the tumor tissue reveals a missense mutation in codon 1212 of the KRAS gene. The patient has no other significant past medical history and her Eastern Cooperative Oncology Group (ECOG) performance status is 00. The medical team plans to initiate a combination cytotoxic chemotherapy regimen. Based on the molecular pathology findings, the addition of a monoclonal antibody directed against which of the following targets is specifically contraindicated due to lack of therapeutic benefit?

  1. Epidermal growth factor receptorAnswer
  2. B
    Vascular endothelial growth factor
  3. C
    Programmed death receptor-1
  4. D
    Cytotoxic T-lymphocyte-associated protein 4
  5. E
    Vascular endothelial growth factor receptor 2

Answer

Epidermal growth factor receptor
Epidermal growth factor receptor (EGFR) signaling is a critical driver of cellular proliferation in colorectal carcinoma. The KRAS gene encodes a small GTPase protein that functions directly downstream of EGFR in the RAS-RAF-MEK-ERK signaling cascade. When a patient has a KRAS mutation (most commonly in codons 12, 13, or 61), the resulting RAS protein remains locked in a constitutively active, GTP-bound state. This leads to continuous downstream signaling and tumor growth regardless of upstream receptor activation. Because the pathway is continuously activated downstream of the receptor, administering monoclonal antibodies that block the upstream Epidermal growth factor receptor (such as cetuximab or panitumumab) provides no therapeutic benefit. Consequently, anti-EGFR therapies are specifically contraindicated in patients with KRAS-mutated colorectal cancer.

Step-by-Step Solution

1
Analyze the patient's diagnosis and molecular profiling results.
The patient has metastatic colorectal cancer with a KRAS codon 12 mutation.
Identifying actionable molecular targets is required to predict therapeutic response and avoid ineffective treatments.
2
Determine the role of the KRAS mutation in tumor intracellular signaling.
Mutated KRAS protein remains in a constitutively active state, causing continuous activation of the downstream RAS-RAF-MEK-ERK pathway regardless of upstream receptor activity.
Understanding the precise location of the mutated protein within the cellular signaling cascade is necessary to anticipate mechanisms of pharmacologic resistance.
3
Identify the targeted therapy class that is contraindicated by this mechanism.
Monoclonal antibodies directed against the Epidermal growth factor receptor (EGFR) are contraindicated because blocking the upstream receptor fails to halt the downstream constitutive signaling driven by the KRAS mutation.
Evidence-based guidelines mandate KRAS testing before initiating anti-EGFR therapies to prevent the administration of ineffective and potentially toxic agents.

Key Concept

Patients with metastatic colorectal cancer harboring KRAS mutations are inherently resistant to anti-EGFR monoclonal antibodies (e.g., cetuximab, panitumumab) because the mutated RAS protein continuously drives cellular proliferation downstream, independent of upstream EGFR blockade.
Rate this question

Topics

Neoplastic Processes

More questions from this topic